News coverage about Check-Cap (NASDAQ:CHEK) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Check-Cap earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.0694386688328 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Check-Cap (NASDAQ CHEK) traded down $0.02 during trading on Tuesday, reaching $1.40. The company had a trading volume of 105,500 shares, compared to its average volume of 40,821. Check-Cap has a 1 year low of $1.17 and a 1 year high of $2.91.

Check-Cap (NASDAQ:CHEK) last posted its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). analysts expect that Check-Cap will post -0.63 earnings per share for the current year.

Several research firms have recently issued reports on CHEK. ValuEngine raised Check-Cap from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective (up previously from $6.00) on shares of Check-Cap in a research report on Thursday, September 28th. Zacks Investment Research upgraded Check-Cap from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Tuesday, October 3rd. Finally, Maxim Group reiterated a “buy” rating and set a $5.00 price objective on shares of Check-Cap in a research report on Wednesday, September 27th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $5.00.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Insider Buying and Selling by Quarter for Check-Cap (NASDAQ:CHEK)

Receive News & Stock Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related stocks with our FREE daily email newsletter.